The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
about
The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis.Identification of protein biomarkers for cervical cancer using human cervicovaginal fluidSquamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma.Detection of serum tumor markers in multiple myeloma using the CLINPROT system.Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients.Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis.LTPB2 acts as a prognostic factor and promotes progression of cervical adenocarcinomaThe prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients.High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma.Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours.Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancerThe assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.Clinical Usefulness of (18)F-FDG PET/CT in the Detection of Early Recurrence in Treated Cervical Cancer Patients with Unexplained Elevation of Serum Tumor Markers.Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation.Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesionsCombined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C.A reusable localized surface plasmon resonance biosensor for quantitative detection of serum squamous cell carcinoma antigen in cervical cancer patients based on silver nanoparticles arrayEndometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.Surgical margins in the veterinary cancer patient.Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer.Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases.Huge right ventricular mass lesion associated with genital malignant tumor: a case report.Analytical assessment of the novel Maglumi squamous cell carcinoma antigen (SCCA) immunoluminometric assay.Diagnostic values of serum tumor markers Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in oral/oropharyngeal squamous cell carcinomaSquamous cell carcinoma antigen in cervical cancer and beyond.Three-dimensional power Doppler ultrasound in cervical carcinoma: monitoring treatment response to radiotherapy.Squamous cell carcinoma antigen, platelet distribution width, and prealbumin collectively as a marker of squamous cell cervical carcinoma.Prognostic significance of the pretreatment serum gamma-glutamyltransferase levels in Chinese patients with non-metastatic cervical cancer.An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases.Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance.Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors.FEZF1 is an Independent Predictive Factor for Recurrence and Promotes Cell Proliferation and Migration in Cervical CancerClinical Value of Combining F-FDG PET/CT and Routine Serum Tumor Markers in The Early Detection of Recurrence Among Follow-up Patients Treated for Cervical Squamous Cell Carcinoma
P2860
Q33648477-EF00CCCC-A42F-40C5-8CD9-DAD919AE35A8Q34172304-EE06BFC1-CC27-45C5-8FD4-39B5D100383AQ34192413-60AF9B6D-2B27-43A8-88C0-D54EDB99EBE4Q34249148-9538FFB0-55FB-4C6A-8BDE-4EE5D0B45164Q34399129-D26384C1-E599-4C58-A2CF-5AA99C25544DQ34579547-7C43C45A-7061-4969-B05D-4E0EFC153116Q35742202-8D9CE96B-82B6-4819-8FA3-7CE4A814795DQ35941311-156D172C-A18D-45F5-9FE6-34BE5C528717Q36107579-8BDE197B-CF17-494F-8AEC-5A8646DC7C4BQ36219980-DB028702-E081-41F0-A10A-8EF8F0B03AF2Q36423023-500A3B23-E80C-4DC7-823C-7BB9CE58883EQ36775127-81C0B87E-AB29-4DDB-9707-E80856E99FFEQ36827736-D1515792-E43C-4EA5-9395-32AB0609D978Q36837576-760C7DA2-9E74-4BAF-8895-B2F8CD543BA3Q37121118-01A93ECB-FDD3-4B8F-9997-B73A877CED70Q37396205-4309EB10-94F7-4CA7-8F0F-AAE51660A5B0Q37511930-822A1014-E3C8-4F42-835C-95A8FFF716BAQ37551343-9593D7A1-DA7A-483F-B7B4-E380DF6EE438Q37607743-DBC6C74F-3BB2-4575-88C8-021ECAB3ECCBQ37608781-EAA3777B-B596-4720-A222-F011E37E6B91Q38757865-9B069C31-63D6-43EE-9A6F-842FEF674AFCQ39473996-0474E671-24AC-427E-ACD3-6758BE601323Q40686865-B384B6BA-FF9D-4242-A202-5A23D3B55563Q41613073-5F669677-7309-4251-9AA2-CAA85C781E3AQ42284405-F8CD562A-06DC-457A-9E3A-AC062B05FCABQ42672827-E6F050D4-B3AB-4B1A-82F0-C60A62E4A8D5Q42734541-9F8591A3-7433-4EF8-9BDD-9BD74BE673D0Q42937598-C414AA90-EB77-4633-9587-34A227AE4570Q43965573-1F1765A3-4C0E-4E16-9E1E-575A57D15F20Q47441316-D6CBBDE7-FC47-474C-A994-4DEF33920564Q49425511-8F33D931-42CF-4249-850E-816EE8C4E6EBQ51491952-40A211AE-1F8B-4414-8C4F-F7B5D1B7BA44Q52593722-698C8CE6-27BF-4E8D-980B-6869E6D1BB05Q54971998-8EE03442-9722-4B27-BF9A-47F6AD4D0039Q55040572-A4506990-BB7C-45BE-A13A-2BDB6114DAF4Q58576736-9BCE19B8-C29B-41F1-9813-5964EE6354B7Q58798374-4260C087-F556-4D4E-9393-D19ECDFA614D
P2860
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The serum assay of tumour mark ...... r: a review of the literature.
@ast
The serum assay of tumour mark ...... r: a review of the literature.
@en
The serum assay of tumour mark ...... r: a review of the literature.
@nl
type
label
The serum assay of tumour mark ...... r: a review of the literature.
@ast
The serum assay of tumour mark ...... r: a review of the literature.
@en
The serum assay of tumour mark ...... r: a review of the literature.
@nl
prefLabel
The serum assay of tumour mark ...... r: a review of the literature.
@ast
The serum assay of tumour mark ...... r: a review of the literature.
@en
The serum assay of tumour mark ...... r: a review of the literature.
@nl
P2093
P1476
The serum assay of tumour mark ...... er: a review of the literature
@en
P2093
Andrea Riccardo Genazzani
Roberta Tana
Stefania Cosio
P356
10.1016/J.CRITREVONC.2007.09.002
P577
2007-10-26T00:00:00Z